Recent strategies to overcome breast cancer resistance
Source : https://pubmed.ncbi.nlm.nih.gov/38615873/
Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast...
Nanoparticle-based strategies show promise in overcoming drug resistance in breast cancer by targeting mechanisms like p-gp activity and hormone imbalance, offering new avenues for enhancing therapeutic outcomes.
Breast Cancer Treatment (PDQ®): Patient Version
Source : https://pubmed.ncbi.nlm.nih.gov/26389406/
This PDQ cancer information summary has current information about the treatment of adult breast cancer. It is meant to inform and help patients, families, and caregivers. It does not give...
PDQ, provided by the NCI under NIH, offers comprehensive, current cancer information in both technical and patient-friendly formats, ensuring accuracy without representing NCI or NIH policy.
Breast Cancer and Therapy-Related Cardiovascular Toxicity
Source : https://pubmed.ncbi.nlm.nih.gov/38769686/
The global incidence of breast cancer is on the rise, a trend also observed in South Korea. However, thanks to the rapid advancements in anticancer therapies, survival rates are improving....
With rising breast cancer incidence, improved survival underscores the need for vigilance in managing treatment-related cardiotoxicity. Vigorous surveillance and protective measures are crucial to enhance post-treatment health and quality of life for survivors.
Trastuzumab deruxtecan in breast cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38621469/
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload...
Trastuzumab deruxtecan (T-DXd) revolutionizes HER2-targeted therapy for metastatic breast cancer, demonstrating efficacy in both HER2-positive and HER2-low cancers, potentially altering treatment paradigms across various settings.
Screening for Breast Cancer: A Comparative Review of Guidelines
Source : https://pubmed.ncbi.nlm.nih.gov/38929759/
Breast cancer is the most common malignancy diagnosed in the female population worldwide and the leading cause of death among perimenopausal women. Screening is essential, since earlier detection in combination...
Consistent guidelines recommend mammography as the primary screening tool for average-risk women aged 40-74, with variations in screening frequency and cessation age based on individual health and life expectancy. Harmonizing international protocols can optimize breast cancer screening effectiveness and clinical guidance.